Literature DB >> 31147410

Refractory pemphigus foliaceous treated with rituximab.

Fatima Awdeh1, Eimear Gilhooley1, Ciara O Grady1, Maureen Connolly1.   

Abstract

Autoimmune blistering diseases are rare but potentially life-threatening conditions. Pemphigus foliaceus is one of these conditions, characterised by superficial erosions of the skin without mucosal involvement. We report the case of a 57-year-old woman who presented with a 4-week history of rash affecting her scalp with associated hair loss. Clinical and histopathological findings were in keeping with pemphigus foliaceus. She was successfully treated with rituximab, a chimeric monoclonal antibody against CD20, leading to a transient depletion of B cells. After 5 months of follow-up, her rash had cleared, and her hair had completely regrown. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  dermatology; pathology

Mesh:

Substances:

Year:  2019        PMID: 31147410      PMCID: PMC6557388          DOI: 10.1136/bcr-2018-229026

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

Review 1.  Current therapy of the pemphigus group.

Authors:  Michael Kasperkiewicz; Enno Schmidt; Detlef Zillikens
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

2.  Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis).

Authors:  Pascal Joly; Noémie Litrowski
Journal:  Clin Dermatol       Date:  2011 Jul-Aug       Impact factor: 3.541

Review 3.  Diagnosis and clinical features of pemphigus foliaceus.

Authors:  Kirk A James; Donna A Culton; Luis A Diaz
Journal:  Dermatol Clin       Date:  2011-07       Impact factor: 3.478

4.  Pemphigus. S2 Guideline for diagnosis and treatment--guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).

Authors:  M Hertl; H Jedlickova; S Karpati; B Marinovic; S Uzun; S Yayli; D Mimouni; L Borradori; C Feliciani; D Ioannides; P Joly; C Kowalewski; G Zambruno; D Zillikens; M F Jonkman
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-10-22       Impact factor: 6.166

5.  British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017.

Authors:  K E Harman; D Brown; L S Exton; R W Groves; P J Hampton; M F Mohd Mustapa; J F Setterfield; P D Yesudian
Journal:  Br J Dermatol       Date:  2017-11       Impact factor: 9.302

6.  Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids.

Authors:  Naif Almugairen; Valerie Hospital; Christophe Bedane; Sophie Duvert-Lehembre; Damien Picard; Anne-Fleur Tronquoy; Estelle Houivet; Michel D'incan; Pascal Joly
Journal:  J Am Acad Dermatol       Date:  2013-07-12       Impact factor: 11.527

7.  First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids.

Authors:  Saskia Ingen-Housz-Oro; Laurence Valeyrie-Allanore; Anne Cosnes; Nicolas Ortonne; Sophie Hüe; Muriel Paul; Pierre Wolkenstein; Olivier Chosidow
Journal:  JAMA Dermatol       Date:  2015-02       Impact factor: 10.282

Review 8.  T cell control in autoimmune bullous skin disorders.

Authors:  Michael Hertl; Rüdiger Eming; Christian Veldman
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

9.  [Successful treatment of pemphigus foliaceus with rituximab. Report of 3 cases].

Authors:  M Alter; M Wittmann; B Völker; A Kapp; T Werfel; R Gutzmer
Journal:  Hautarzt       Date:  2009-09       Impact factor: 0.751

Review 10.  Immunopathology and molecular diagnosis of autoimmune bullous diseases.

Authors:  Sidonia Mihai; Cassian Sitaru
Journal:  J Cell Mol Med       Date:  2007 May-Jun       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.